Bio-Techne ( (TECH) ) has released its Q4 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding scientific investigations and drug discovery efforts. With a diverse product portfolio, the company serves the biopharma and academic research communities worldwide.
In its latest earnings report for the fourth quarter of fiscal 2025, Bio-Techne reported a 4% increase in net sales, reaching $317 million, with full-year sales totaling $1.2 billion. Despite a challenging market environment, the company achieved a solid performance in its cell therapy and protein analysis segments.
The company’s adjusted earnings per share (EPS) rose to $0.53 in the fourth quarter, up from $0.49 the previous year, while the full-year adjusted EPS increased to $1.92. The Protein Sciences segment saw a 6% increase in sales for the quarter, driven by strong demand for its specialized proteins and analytical platforms. However, the Diagnostics and Spatial Biology segment experienced a slight decline in quarterly sales, impacted by an unfavorable product mix.
Bio-Techne announced the divestiture of its Exosome Diagnostics business to focus on high-growth areas, particularly in research and precision diagnostics. This strategic move is expected to enhance profitability and align with the company’s investment priorities.
Looking ahead, Bio-Techne remains optimistic about navigating market uncertainties and delivering value to stakeholders, leveraging its innovative solutions and strong market position.